ECSP21052586A - Glutarato de 3-(1,2,3,6-tetrahidropiridin-2-il)piridina o un solvato farmacéuticamente aceptable del mismo - Google Patents

Glutarato de 3-(1,2,3,6-tetrahidropiridin-2-il)piridina o un solvato farmacéuticamente aceptable del mismo

Info

Publication number
ECSP21052586A
ECSP21052586A ECSENADI202152586A ECDI202152586A ECSP21052586A EC SP21052586 A ECSP21052586 A EC SP21052586A EC SENADI202152586 A ECSENADI202152586 A EC SENADI202152586A EC DI202152586 A ECDI202152586 A EC DI202152586A EC SP21052586 A ECSP21052586 A EC SP21052586A
Authority
EC
Ecuador
Prior art keywords
tetrahydropyridin
pharmaceutically acceptable
acceptable solvate
same
glutarate
Prior art date
Application number
ECSENADI202152586A
Other languages
English (en)
Inventor
Anatoly Mazurov
Original Assignee
Philip Morris Products Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philip Morris Products Sa filed Critical Philip Morris Products Sa
Publication of ECSP21052586A publication Critical patent/ECSP21052586A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere al glutarato de 3-(1,2,3,6-tetrahidropiridin-2-il)piridina o un solvato farmacéuticamente aceptable del mismo, a un cristal del mismo y a un polimorfo de este cristal. Además, se refiere al uso medicinal de cada uno de estos, en particular en el tratamiento o la profilaxis de la adicción a sustancias o la inflamación
ECSENADI202152586A 2018-12-17 2021-07-16 Glutarato de 3-(1,2,3,6-tetrahidropiridin-2-il)piridina o un solvato farmacéuticamente aceptable del mismo ECSP21052586A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18213200 2018-12-17

Publications (1)

Publication Number Publication Date
ECSP21052586A true ECSP21052586A (es) 2021-08-31

Family

ID=64744512

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202152586A ECSP21052586A (es) 2018-12-17 2021-07-16 Glutarato de 3-(1,2,3,6-tetrahidropiridin-2-il)piridina o un solvato farmacéuticamente aceptable del mismo

Country Status (19)

Country Link
US (1) US20210395218A1 (es)
EP (1) EP3898607B1 (es)
JP (1) JP2022514283A (es)
KR (1) KR20210104666A (es)
CN (1) CN113039180A (es)
AU (1) AU2019407661A1 (es)
BR (1) BR112021009580A2 (es)
CA (1) CA3116524A1 (es)
CL (1) CL2021001583A1 (es)
CO (1) CO2021009186A2 (es)
EC (1) ECSP21052586A (es)
ES (1) ES2964561T3 (es)
HU (1) HUE063731T2 (es)
IL (1) IL283923A (es)
MX (1) MX2021006867A (es)
PH (1) PH12021550875A1 (es)
PL (1) PL3898607T3 (es)
WO (1) WO2020127225A1 (es)
ZA (1) ZA202102058B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023540190A (ja) 2020-09-03 2023-09-22 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 低吸湿性活性粉末組成物
CN116033891A (zh) 2020-09-03 2023-04-28 菲利普莫里斯生产公司 冷冻干燥的低吸湿性活性粉末组合物
US20230346696A1 (en) 2020-09-03 2023-11-02 Philip Morris Products S.A. Spray dried low hygroscopicity active powder compositions
US20240058314A1 (en) * 2021-01-07 2024-02-22 Philip Morris Products S.A. Compositions comprising anatabine and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US5942244A (en) 1997-07-31 1999-08-24 Farmo-Nat Ltd. Local oral herbal slow release tablets
US6090411A (en) 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CN2719043Y (zh) 2004-04-14 2005-08-24 韩力 雾化电子烟
CA2794097C (en) 2010-03-23 2016-08-09 Rock Creek Pharmaceuticals, Inc. Use of anatabine to treat inflammation and methods of synthesizing anatabine
US8207346B2 (en) * 2010-03-23 2012-06-26 Rock Creek Pharmaceuticals, Inc. Methods of synthesizing anatabine
US8241680B2 (en) 2010-06-30 2012-08-14 Rock Creek Pharmaceuticals, Inc. Nutraceutical product containing anatabine and yerba maté
JP5934796B2 (ja) * 2011-08-29 2016-06-15 アールシーピー ディベロップメント インコーポレイテッド 抗炎症補助のための製品
WO2015009500A1 (en) 2013-07-19 2015-01-22 Williams Jonnie R Volatilized delivery of anatabine for treatment of substance addiction

Also Published As

Publication number Publication date
HUE063731T2 (hu) 2024-01-28
JP2022514283A (ja) 2022-02-10
BR112021009580A2 (pt) 2021-08-17
PH12021550875A1 (en) 2021-10-18
CA3116524A1 (en) 2020-06-25
CN113039180A (zh) 2021-06-25
US20210395218A1 (en) 2021-12-23
CL2021001583A1 (es) 2021-11-26
KR20210104666A (ko) 2021-08-25
ES2964561T3 (es) 2024-04-08
IL283923A (en) 2021-07-29
CO2021009186A2 (es) 2021-08-30
EP3898607A1 (en) 2021-10-27
EP3898607C0 (en) 2023-10-18
MX2021006867A (es) 2021-07-02
ZA202102058B (en) 2022-09-28
EP3898607B1 (en) 2023-10-18
PL3898607T3 (pl) 2024-03-18
WO2020127225A1 (en) 2020-06-25
AU2019407661A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
ECSP21052586A (es) Glutarato de 3-(1,2,3,6-tetrahidropiridin-2-il)piridina o un solvato farmacéuticamente aceptable del mismo
CR20170411A (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
ECSP18002929A (es) Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
EA202091483A1 (ru) Амидзамещенные индольные соединения, пригодные в качестве ингибиторов tlr
MX2018006223A (es) Moduladores de ror-gamma.
PH12016501457B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
CL2016001364A1 (es) Moduladores de ror gamma (rory)
MY182454A (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
GT201500235A (es) Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3)
PH12021500012A1 (en) Inhibitors of keapi-nrf2 protein-protein interaction
MX2017015737A (es) Moduladores de ror gamma (ror?).
PH12017550077A1 (en) C-3 novel triterpenone with c-17 reverse amide derivatives as hiv inhibitors
PH12019500568A1 (en) Dopamine-b-hydroxylase inhibitors
ZA202003281B (en) Heterocycle substituted pyridine derivative antifungal agents
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
MX2019012522A (es) Compuestos y metodos terapeuticos.
AR110481A1 (es) MODULADORES DE ROR g (RORg)
WO2015198263A3 (en) Novel betulinic proline substituted derivatives as hiv inhibitors
DK3937948T3 (da) Phytoecdysoner og derivater deraf til anvendelse i behandlingen af neuromuskulære sygdomme
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors